JAK1 and rheumatoid arthritis: Baricitinib, an oral inhibitor of Janus kinase (JAK)1 and JAK2 (Fridman et al, 2010) approved for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA) in adults, was independently hypothesized to be a therapeutic option for COVID‐19.